Sort
10,766 grants matching “checkpoint inhibitor”
Head & Neck Cancer Neoantigen Characterization & Therapeutic Targeting
$461,830Young J. Kim · Vanderbilt University Medical Center · R01 · FY2020 · DE
Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions
$461,591George Georgiou Georgiou · University Of Texas At Austin · U01 · FY2023 · AI
Modulation of tumor inflammatory factor for immune therapy
$461,550Shu-Hsia Chen · Methodist Hospital Research Institute · R01 · FY2017 · CA
Interplay between tumor and microenvironment in bone metastasis
$461,537Paul B Fisher · Virginia Commonwealth University · R01 · FY2022 · CA
Interplay between tumor and microenvironment in bone metastasis
$461,537Paul B Fisher · Virginia Commonwealth University · R01 · FY2023 · CA
Evaluation of Novel Radiation Modifiers
$461,536Deborah Citrin · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity
$461,446David G Denardo · Washington University · U01 · FY2025 · CA
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
$461,416Manish Bais · Boston University Medical Campus · R01 · FY2025 · DE
Effect of DNA repeat silencing on efficacy of ATRi in prostate cancer treatment
$461,391Eric J Brown · University Of Pennsylvania · R01 · FY2023 · CA
Vaccine Targeting of RCC Blood Vessels to Promote TME Normalization and Enhance TIL Recruitment
$461,363Walter J Storkus · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Targeting UHRF1 in combinational immunotherapy
$461,315Xiao-Fan Wang · Duke University · R01 · FY2022 · CA
Targeting Posttranslational Modifications in Breast Carcinogenesis
$461,234Yong Wan · Northwestern University At Chicago · R01 · FY2020 · CA
Systematic, molecular level analysis of the Fc receptor ligation on antibody effector functions
$461,177George Georgiou Georgiou · University Of Texas At Austin · U01 · FY2024 · AI
LKB1/AMPK Signaling and Peutz-Jeghers Syndrome
$461,147Lewis C Cantley · Brigham And Women'S Hospital · P01 · FY2009 · CA
GENOTOXIC RESPONSES
$461,120Trey Ideker · University Of California, San Diego · P50 · FY2014 · GM
Targeting of a Major Immune Evasion Pathway in Triple-negative Breast Cancer
$461,120Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Targeting UHRF1 in combinational immunotherapy
$461,025Xiao-Fan Wang · Duke University · R01 · FY2023 · CA
Epigenetic Synergy Between DNMT and EZH1/2 Inhibitors for Therapy in Solid Tumors
$460,981Scott Rothbart · Coriell Institute For Medical Research · P50 · FY2024 · CA
Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer
$460,977Yurij Ionov · Roswell Park Cancer Institute Corp · R21 · FY2024 · CA
Cell-Selective CpG-STAT3 Inhibitors for Radioimmunotherapy of Malignant Glioma
$460,943Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA
Central mechanisms of glucocorticoid circadian rhythm dysfunction in breast cancer
$460,829Jeremy Borniger · Cold Spring Harbor Laboratory · R01 · FY2025 · CA
Targeting Epigenomic Regulators at the Replication Fork in PDAC
$460,768Gwen Lomberk · Medical College Of Wisconsin · R01 · FY2025 · CA
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
$460,749Shruthi Naik · Mayo Clinic Rochester · U01 · FY2025 · CA
RCAN 1.4 metastasis suppressor in thyroid cancer
$460,722Matthew D Ringel · Ohio State University · R01 · FY2021 · CA
Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC
$460,674Judith A. Varner · University Of California, San Diego · R01 · FY2019 · CA